Destiny Pharma plc
("Destiny Pharma" or "the Company")
Notice of XF Pipeline Update Meeting
Brighton, United Kingdom - 27 September 2023 - Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, today announces that it will host a meeting for analysts and investors on its XF product pipeline on Tuesday, 17 October 2023 at 2:00pm BST / 9:00am EDT.
The meeting will be held in person at the offices of Cavendish, 1 Bartholomew Close, London, EC1A 7BL, alongside the option of virtual attendance via the Investor Meet platform.
The meeting, which is scheduled to last around two hours, will be led by Chris Tovey, Chief Executive Officer, and will feature presentations from the management team on the products and potential of the XF product pipeline. The meeting will also feature discussions from external speakers as follows:
· Professor Mark Wilcox, Consultant Microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospital and member of Destiny Pharma's Scientific Advisory Board: Presentation of the issue of surgical site infections and its impact on the healthcare system and patients
· Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD Anderson Cancer Center and Mr Raghbir Khakha, Consultant Trauma and Orthopaedic Surgeon at Guy's and St Thomas's Hospital: Discussion of the reality on the wards
No new material disclosures will be made during the meeting and the presentation will be made available on the Company's website.
There will be an opportunity for Q&A with the speakers and Destiny Pharma's management team.
Prior registration for the event is required. To attend in person please contact RD@destinypharma.com.
To attend virtually, investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited to the event.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
For further information on the Company, please visit www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.